Europass Personal Information PASELLO GIULIAioveneto.it › wp-content › uploads › 2019 › 05...

Pagina 1 / 15 - Curriculum vitae di PASELLO GIULIA

Per maggiori informazioni su Europass: http://europass.cedefop.europa.eu © Unione europea, 2002-2010 24082010

Curriculum Vitae

Europass

Personal Information

Surname(s) / Name(s) PASELLO GIULIA

TAX CODE

Nationality

PSLGLI79R57L407G

Italian

Date of birdth 17/10/1979

Gender

Tel

Email:

Female

+390498215608

[email protected]

Occupational Field Medical Oncology

Work experience

Dates

Occupation or position held

Main activities and responsabilities

Name and address of employer

Type of business or sector

Dates

07/01/2014-current position

Associate Medical Director

Clinical and research activity in thoracic oncology

Second Medical Oncology Unit, Istituto Oncologico

Veneto, Via Gattamelata 64, 35128 Padua (Italy)

Medical Oncology

01/02/2010- 06/01/2014

Occupation or position held Medical Oncologist (with contract)

Main activities and responsabilities Clinical and research activity in thoracic oncology

Name and address of employer Second Medical Oncology Unit, Istituto Oncologico

Veneto, Via Gattamelata 64, 35128 Padua (Italy)

Type of business or sector Medical oncology

Dates 01/07/2009 - 01/12/2009



Occupation or position held Fellow

Main activities and responsabilities Basic research about malignant pleural mesothelioma

Name and address of employer Molecular Oncology laboratories, University of Zurich

(Switzerland), Prof. Rolf Stahel

Type of business or sector Molecular Oncology

Dates 01/07/2008 - 31/12/2008

Occupation or position held Resident in Medical Oncology

Main activities and responsabilities Clinical management of oncological pediatric patients

Name and address of employer Pediatric oncohematology, University of Padua (Italy)

Type of business or sector Pediatric Oncology and Haematology

Dates 01/07/2007 - 31/12/2009


Main activities and responsabilities Clinical management and research in Oncology

Name and address of employer Second Medical Oncology Unit, Istituto Oncologico

Veneto

Padua (Italy)

Type of business or sector Medical Oncology

Dates 01/01/2006 - 30/06/2007


Main activities and responsabilities Basic and translational research in oncology

Name and address of employer Oncological and Surgical Science Department, Oncology

Section, University of Padua (Italy)

Type of business or sector Molecular Oncology

Education and Training

Dates 01/01/2012-31/12/2014

Title of qualification awarded PhD

Principal subjects/occupational

skills covered

Neoangiogenic biomarkers and therapeutic targets in

malignant pleural mesothelioma



Dates 01/01/2006 - 31/12/2010

Title of qualification awarded Residency in Medical Oncology

Principal subjects/occupational

skills covered

Medical Oncology

Name and type of organisation

providing education and training

University of Padua (Italy)

Dates 01/10/1999 - 11/10/2005

Title of qualification awarded Graduation in medicine and surgery

Name and type of organisation

providing education and training

Number of medical register subscription

Other training experiences

University of Ferrara (Ferrara, Italy)

TV04727

March 2014: admitted at the 13th ESO ESMO Masterclass

in Clinical Oncology where she attended plenary lectures

regarding state-of-the-art clinical evaluation and

treatments in oncology. As a selected participant the

applicant presented a research abstract which was

selected for publication and had the opportunity to

present and discuss with the faculty clinical cases of

thoracic cancer.

Personal skills and competences

Mother tongue(s) Italian

Other language(s) English: excellent reading, writing, speaking

Organisational skills and

competences

Experience in clinical trial partecipation according to

GCP rules:

-Participation as Co-Investigator to about 40 clinical trials

in the field of thoracic oncology;

- Principal Investigator of about 15 clinical trials in the



Awards and Grants

field of thoracic oncology (Lung Cancer, Malignant

Pleural Mesothelioma, Thymic malignancies).

-Clinical and translational research projects design and

conduction.

- 2015: recipient of My First AIRC Grant for the

translational project “MET-targeting in Small Cell

Lung Cancer)

- 2014 ‘Saro Leggio’ award of the Associazione Italiana

Ricerca Patologie Polmonari (AIRPP) for translational

study of malignant pleural mesothelioma

- 2012: recipient of IMIG (International Mesothelioma

Interest group) travel award

- 2010-2011: recipient of ESMO (European Society for

Medical Oncology) translational research fellowship

award for the project “Identification of novel molecular

targets and biological agents for the chemotherapy of

Malignant Pleural Mesothelioma”

List of publications:

IF: 200,596 (06 nov 2018)

H INDEX : 10 (06 nov 2018)

Citations: 326 (06 nov 2018)

FULL PAPER PUBLICATIONS IN PEER REVIEWED

JOURNALS WITH IMPACT FACTOR

1) Pasello G, Agata S, Bonaldi L, Corradin A,

Montagna M, Zamarchi R, Parenti A, Cagol M, Zaninotto

G, Ruol A, Ancona E, Amadori A and Saggioro D.“DNA

copy number alterations correlate with survival of

oesophageal adenocarcinoma patients”. Modern

Patology, 2009;22 (1):58-65.

IF: 5.485



2) Favaretto A, Pasello G, Magro C, Schettino C, Gridelli

C. “Second and third line treatment in non-small-cell

lung cancer”. Crit Rev Oncol Hematol, 2009; 71 (2):117-

126

IF: 5.039

3) Favaretto A, Pasello G, Loreggian L, Breda C, Braccioni

F, Marulli G, Stragliotto S, Magro C, Sotti G, Rea F.

“Preoperative concomitant chemo-radiotherapy (CT-RT)

in Superior Sulcus Tumor (SST): a mono-institutional

experience”. Lung Cancer, 2010 May; 68(2):228-33

IF: 3.767

4) Pasello G and Favaretto A. “Molecular targets in

malignant pleural mesotelioma treatment”. Current Drug

Targets, 2009; 10: 1235-1244.

IF: 3.029

5) Sidi R*, Pasello G*, Opitz I, Soltermann A, Tutic M,

Rehrauer H, Weder W, Stahel RA, Felley-Bosco E. *Equal

contributors “Induction of senescence markers after neo-

adjuvant chemotherapy of malignant pleural

mesothelioma and association with clinical outcome: An

exploratory analysis”. Eur J Cancer, 2011; 47 (2): 326-32.

IF: 6.163

6) Bonanno L, Schiavon M, Nardo G, Bertorelle R, Bonaldi

L, Galligioni A, Indraccolo S, Pasello G, Rea F and

Favaretto A. “Prognostic and Predictive Implications of

EGFR mutations, EGFR copy number and KRAS mutations

in advanced stage lung adenocarcinoma”. Anticancer

Research 2010; 30: 5121-5128

IF: 1.895

7) Gridelli C, Morgillo F, Favaretto A, de Marinis F, Chella

A, Cerea G, Mattioli R, Tortora G, Rossi A, Fasano M,

Pasello G, Ricciardi S, Maione P, Di Maio M &

Ciardiello F. “Sorafenib in combination with erlotinib or

http://www.ncbi.nlm.nih.gov/pubmed/21036600






with gemcitabine in elderly patients with advanced non-

small-cell lung cancer: a randomized phase II study”

Annals of Oncology, 2011; 22 (7): 1528-34

11.855

8) Pasello G, Nicotra S, Marulli G, Rea F, Bonanno L, Carli

P, Magro C, Jirillo A, Favaretto A. “Platinum-based

doublet chemotherapy in pre-treated malignant pleural

mesothelioma (MPM) patients: A mono-institutional

experience” Lung Cancer, 2011;73: 351-355

IF: 3.767

9) Rumiato E, Pasello G, Montagna M, Scaini MC, De

Salvo GL, Parenti A, Cagol M, Ruol A, Ancona E, Amadori

A, Saggioro D. “DNA copy number profile discriminates

between esophageal adenocarcinoma and squamous cell

carcinoma and represents an independent prognostic

parameter in esophageal adenocarcinoma”. Cancer

Letters, 2011; 310 (1): 84-9

IF: 5.992

10) Gridelli C, Gallo C, Morabito A, Iaffaioli RV, Favaretto

A, Isa L, Barbera S, Gamucci T, Ceribelli A, Filipazzi V,

Maione P, Rossi A, Barletta E, Signoriello S, De Maio E,

Piccirillo MC, Di Maio M, Rocco G, Vecchione A, Perrone

F; G-STEP Investigators “Phase I-II trial of gemcitabine-

based first-line chemotherapies for small cell lung cancer

in elderly patients with performance status 0-2: the G-

STEP trial” J Thorac Oncol. 2012 Jan;7(1):233-42

IF: 5.040

11) Pasello G, Ceresoli GL, Favaretto A “An overview of

neoadjuvant chemotherapy in the multimodality

treatment of malignant pleural mesotelioma”. Cancer

Treat Rev. 2013 Feb;39 (1):10-7

IF: 7.983

12) Di Maio M, Leighl NB, Gallo C, Feld R, Ciardiello F,

http://www.ncbi.nlm.nih.gov/pubmed?term=%2522Rumiato%20E%2522%255BAuthor%255D

http://www.ncbi.nlm.nih.gov/pubmed?term=%2522Pasello%20G%2522%255BAuthor%255D

http://www.ncbi.nlm.nih.gov/pubmed?term=%2522Montagna%20M%2522%255BAuthor%255D

http://www.ncbi.nlm.nih.gov/pubmed?term=%2522Scaini%20MC%2522%255BAuthor%255D

http://www.ncbi.nlm.nih.gov/pubmed?term=%2522De%20Salvo%20GL%2522%255BAuthor%255D

http://www.ncbi.nlm.nih.gov/pubmed?term=%2522De%20Salvo%20GL%2522%255BAuthor%255D

http://www.ncbi.nlm.nih.gov/pubmed?term=%2522Parenti%20A%2522%255BAuthor%255D

http://www.ncbi.nlm.nih.gov/pubmed?term=%2522Cagol%20M%2522%255BAuthor%255D

http://www.ncbi.nlm.nih.gov/pubmed?term=%2522Ruol%20A%2522%255BAuthor%255D

http://www.ncbi.nlm.nih.gov/pubmed?term=%2522Ancona%20E%2522%255BAuthor%255D

http://www.ncbi.nlm.nih.gov/pubmed?term=%2522Amadori%20A%2522%255BAuthor%255D

http://www.ncbi.nlm.nih.gov/pubmed?term=%2522Amadori%20A%2522%255BAuthor%255D

http://www.ncbi.nlm.nih.gov/pubmed?term=%2522Saggioro%20D%2522%255BAuthor%255D



Butts C, Maione P, Gebbia V, Morgillo F, Wierzbicki R,

Favaretto A, Alam Y, Cinieri S, Siena S, Bianco R, Riccardi

F, Spatafora M, Ravaioli A, Felletti R, Fregoni V,

Genestreti G, Rossi A, Mancuso G, Fasano M, Morabito

A, Tsao MS, Signoriello S, Perrone F, Gridelli C; TORCH

Investigators. “Quality of life analysis of TORCH, a

randomized trial testing first-line erlotinib followed by

second-line cisplatin/gemcitabine chemotherapy in

advanced non-small-cell lung cancer.” J Thorac Oncol.

2012 Dec;7 (12):1830-4

IF: 5.040

13) Pasello G, Marulli G, Polo V, Breda C, Bonanno L,

Loreggian L, Rea F, Favaretto A. “Pemetrexed plus

carboplatin or cisplatin as neoadjuvant treatment of

operable malignant pleural mesothelioma (MPM)”

Anticancer Res. 2012 Dec;32 (12):5393-9.

IF: 1.895

14) Marulli G, Di Chiara F, Braccioni F, Perissinotto E,

Pasello G, Gino Favaretto A, Breda C, Rea F. “Changes in

pulmonary function tests predict radiological response to

chemotherapy in malignant pleural mesothelioma” Eur J

Cardiothorac Surg. 2013 Jul; 44 (1):104-10

IF: 2.803

15) Pasello G, Urso L, Conte P, Favaretto A. “Effects of

Sulfonylureas on Tumor Growth: A Review of the

Literature”. The Oncologist 2013, 18(10):1118-1125

IF: 4.789

16) Ceresoli GL, Grosso F, Zucali PA, Mencoboni M,

Pasello G, Ripa C, Degiovanni D, Simonelli M, Bruzzone

A, Dipietrantonj C, Piccolini E, Beretta GD, Favaretto AG,

Giordano L, Santoro A, Botta M. “Prognostic factors in

elderly patients with malignant pleural mesothelioma:

results of a multicenter survey.” Br J Cancer. 2014 Jul






15;111(2):220-6.

IF: 5.569

17) Marulli G, Verderi E, Zuin A, Schiavon M, Battistella L,

Perissinotto E, Romanello P, Favaretto AG, Pasello G, Rea

F. “Outcomes and prognostic factors of non-small-cell

lung cancer with lymph node involvement treated with

induction treatment and surgical resection.”

Interact Cardiovasc Thorac Surg. 2014 Aug;19(2):256-62

IF: 1.329

18) Pasello G, Urso L, Silic-Benussi M, Schiavon M,

Cavallari I, Marulli G, Nannini N, Rea F, Ciminale V,

Favaretto A. “Synergistic antitumor activity of

recombinant human Apo2L/TRAIL in combination with

Carboplatin and Pemetrexed in Malignant Pleural

Mesothelioma”. J Thorac Oncol 2014, 2014 Jul;9(7):1008-

17

IF: 5.040

19) Schiavon M, Marulli G, Nannini N, Pasello G, Lunardi

F, Balestro E, Perissinotto E, Rebusso A, Saetta M, Rea F,

Calabrese F. “COPD-related adenocarcinoma presents

low aggressiveness morphological and molecular

features compared to smoker tumours”. Lung Cancer.

2014 Dec;86(3):311-7.

IF: 3.767

20) Marulli G, Battistella L, Perissinotto E, Breda C,

Favaretto AG, Pasello G, Zuin A, Loreggian L, Schiavon M,

Rea F.”Results of surgical resection after induction

chemoradiation for Pancoast tumours †.”

Interact Cardiovasc Thorac Surg. 2015 Jun;20(6):805-11

IF: 1.329

21) Pasello G, Carli P, Canova F, Bonanno L, Polo V, Zago

G, Urso L, Conte P, Favaretto A. “Epirubicin plus

paclitaxel regimen as second-line treatment of patients













with small-cell lung cancer.” Anticancer Res. 2015

Apr;35(4):2183-9.

IF: 1.895

22) Urso L, Calabrese F, Favaretto A, Conte PF and

Pasello G. “Critical review about MDM2 in cancer:

possible role in malignant mesothelioma and

implications for treatment” Critical Review in Oncology

and Hematology 2016 Jan;97:220-30

IF: 5.039

23) Pasello G, Urso L, Mencoboni M, Grosso F, Ceresoli GL,

Lunardi F, Vuljan SE, Bertorelle R, Sacchetto V, Ciminale V,

Rea F, Favaretto A, Conte PF, Calabrese F. “MDM2 and

HIF1alpha expression levels in different histologic

subtypes of Malignant Pleural Mesothelioma: correlation

with pathological and clinical data.” Oncotarget, 2015 Dec

8;6(39):42053-66

IF: 5.008

24) Ferrazzi A, Russo I, Pasello G, Alaibac M. “Atypical skin

reaction in a patient treated with gefitinib for advanced

lung cancer: A case report and review of the literature”.

Exp Ther Med. 2016 Jan;11(1):197-200

IF: 1.56

25) Polo V, Pasello G, Frega S, Favaretto A, Koussis H,

Conte P, Bonanno L.” Squamous cell carcinomas of the

lung and of the head and neck: new insights on molecular

characterization.” Oncotarget. 2016 May 3;7(18):25050-

63

IF: 5.008

26) Frega S, Conte P, Fassan M, Polo V, Pasello G. A Triple

Rare E709K and L833V/H835L EGFR Mutation Responsive

to an Irreversible Pan-HER Inhibitor: A Case Report of

Lung Adenocarcinoma Treated with Afatinib.

J Thorac Oncol. 2016 May;11(5):e63-4


https://www.ncbi.nlm.nih.gov/pubmed/26889239












IF: 5.040

27) Bonanno L, Zago G, Marulli G, Del Bianco P, Schiavon

M, Pasello G, Polo V, Canova F, Tonetto F, Loreggian L,

Rea F, Conte P, Favaretto A. “Radiological response and

survival in locally advanced non-small-cell lung cancer

patients treated with three-drug induction chemotherapy

followed by radical local treatment.”

Onco Targets Ther. 2016 Jun 21;9:3671-81

IF: 2.311

28) Valentina Polo, Giulia Pasello. “Multimodality

treatment in limited small cell lung cancer (L-SCLC):

different perspectives about the optimal approach” .

Transl Cancer Res Vol 5, Supplement 2 (August 2016):

IF: 1.757

29) Russo I, Sacco G, Frega S, Polo V, Pasello G, Alaibac

M. “Immunotherapy-related skin toxicity: bullous

pemphigoid in a lung adenocarcinoma patient treated

with the anti-PDL1 antibody atezolizumab.” Eur J

Dermatol. 2017 Mar 1. doi: 10.1684/ejd.2016.2959.

IF: 2.069

30) Stefano Frega, Martina Lorenzi, Matteo Fassan,

Stefano Indraccolo, Fiorella Calabrese, Adolfo Favaretto,

Laura Bonanno, Valentina Polo, Giulia Zago, Francesca

Lunardi, Ilaria Attili, Alberto Pavan, Massimo Rugge,

Valentina Guarneri, PierFranco Conte, Giulia Pasello6.

“Clinical features and treatment outcome of non-small

cell lung cancer (NSCLC) patients with uncommon or

complex epidermal growth factor receptor (EGFR)

mutations” Oncotarget March 2017 DOI:

10.18632/oncotarget.15945

IF: 5.008

31) Mencoboni M, Filiberti RA, Taveggia P, Grosso F,

Pasello G, Del Corso L, Muzio A, Polo V, Zucali P, Ceresoli





http://tcr.amegroups.com/issue/view/190






GL, Soto Parra HJ, Auriati L, Simonassi C. “Clinical

Features and Treatment Outcome of Malignant Pleural

Mesothelioma.”

Oncol Res Treat. 2017;40(6):364-369.

IF: 1.333

32) Urso L, Cavallari I, Silic-Benussi M, Biasini L, Zago G,

Calabrese F, Conte PF, Ciminale V, Pasello G. “Synergistic

targeting of malignant pleural mesothelioma cells by

MDM2 inhibitors and TRAIL agonists.”

Oncotarget. 2017 May 11.

IF: 5.008

33) Gobbini E, Pilotto S, Pasello G, Polo V, Di Maio M,

Arizio F, Galetta D, Petrillo P, Chiari R, Matocci R, Di

Costanzo A, Di Stefano TS, Aglietta M, Cagnazzo C,

Sperduti I, Bria E, Novello S. “Effect of Contract Research

Organization Bureaucracy in Clinical Trial Management:

A Model From Lung Cancer.”

Clin Lung Cancer. 2017 Oct 28. pii: S1525-

7304(17)30306-6.

IF: 3.434

34) Zucali PA, De Pas T, Palmieri G, Favaretto A, Chella A,

Tiseo M, Caruso M, Simonelli M, Perrino M, De Vincenzo F,

Toffalorio F, Damiano V, Pasello G, Garbella E, Ali M,

Conforti F, Ottaviano M, Cioffi A, De Placido S, Giordano L,

Bertossi M, Destro A, Di Tommaso L, Santoro A. “Phase II

Study of Everolimus in Patients With Thymoma and Thymic

Carcinoma Previously Treated With Cisplatin-Based

Chemotherapy.”

J Clin Oncol. 2017 Dec 14:JCO2017744078

IF: 24.008

35) Pasello G, Zago G, Lunardi F, Urso L, Kern I, Vlacic G,

Grosso F, Mencoboni M, Ceresoli GL, Schiavon M, Pezzuto

F, Pavan A, Vuljan SE, Del Bianco P, Conte P, Rea F,
















Additional information

Calabrese F. “Malignant pleural mesothelioma immune

microenvironment and checkpoint expression: correlation

with clinical-pathological features and intra-tumor

heterogeneity over time.” Ann Oncol. 2018 Mar 5. doi:

10.1093/annonc/mdy086

IF: 11.855

36) Frega S, Bonanno L, Guarneri V, Conte P, Pasello G.

Therapeutic perspectives for brain metastases in non-

oncogene addicted non-small cell lung cancer (NSCLC):

Towards a less dismal future? Crit Rev Oncol Hematol.

2018 Aug;128:19-29.

IF:5.039

37) Imbimbo M, Vitali M, Fabbri A, Ottaviano M, Pasello G,

Petrini I, Palmieri G, Berardi R, Zucali P, Ganzinelli M,

Marabese M, Broggini M, Marino M, Trama A, Rulli E,

Hollander L, Pruneri G, Torri V, Garassino MC. RELEVENT

Trial: Phase II Trial of Ramucirumab, Carboplatin, and

Paclitaxel in Previously Untreated Thymic Carcinoma/B3

Thymoma With Area of Carcinoma.

Clin Lung Cancer. 2018 Jul 3. pii: S1525-7304(18)30164-5

IF: 3.434

38) Bonanno L, Pavan A, Dieci MV, Di Liso E, Schiavon M,

Comacchio G, Attili I, Pasello G, Calabrese F, Rea F,

Favaretto A, Rugge M, Guarneri V, Fassan M, Conte PF

The role of immune microenvironment in small-cell lung

cancer: Distribution of PD-L1 expression and prognostic

role of FOXP3-positive tumour infiltrating lymphocytes.

Eur J Cancer. 2018 Aug 1;101:191-200. doi:

10.1016/j.ejca.2018.06.023. [Epub ahead of print]

IF: 7.191

39) Pelosi G, Papotti M, Righi L, Rossi G, Ferrero S, Bosari S,

Calabrese F, Kern I, Maisonneuve P, Sonzogni A, Albini A,

Harari S, Barbieri F, Capelletto E, Catino AM, Cavone D, De

















Palma A, Fusco N, Lunardi F, Maiorano E, Marzullo A,

Novello S, Papanikolaou N, Pasello G, Pennella A, Pezzuto

F, Punzi A, Prisciandaro E, Rea F, Rosso L, Scattone A, Serio

G. Pathologic Grading of Malignant Pleural Mesothelioma:

An Evidence-Based Proposal.

J Thorac Oncol. 2018 Nov;13(11):1750-1761

IF: 5.040

40) Imbimbo M, Ottaviano M, Vitali M, Fabbri A, Leuzzi G,

Fiore M, Franceschini D, Pasello G, Perrino M, Schiavon M,

Pruneri G, Dei Tos AP, Sangalli C, Garassino MC, Berardi R,

Alessi A, Calareso G, Petrini I, Scorsetti M, Scotti V, Rosso L,

Rea F, Pastorino U, Casali PG, Ramella S, Ricardi U, Abate-

Daga L, Torri V, Trama A, Palmieri G, Marino M, Zucali PA.

Best practices for the management of thymic epithelial

tumors: A position paper by the Italian collaborative group

for ThYmic MalignanciEs (TYME). Cancer Treat Rev. 2018

Oct 5;71:76-87.

IF: 7.983

41) Pasello G, Vicario G, Zustovich F, Oniga F, Gori S,

Rosetti F, Bonetti A, Favaretto A, Toso S, Redelotti R, Santo

A, Bernardi D, Giovanis P, Oliani C, Calvetti L, Gatti C,

Palazzolo G, Baretta Z, Bortolami A, Bonanno L, Basso M,

Menis J, Corte DD, Frega S, Guarneri V, Conte P; Veneto

Oncology Network From Diagnostic-Therapeutic Pathways

to Real-World Data: A Multicenter Prospective Study on

Upfront Treatment for EGFR-Positive Non-Small Cell Lung

Cancer (MOST Study). Oncologist. 2019 Mar 7.

IF

42. Comacchio GM, Schiavon M, Azzolina D, Mammana

M, Marulli G, Zuin A, Verderi E, Monaci N, Bonanno

L, Pasello G, Rea F. Does Induction Therapy Increase

Anastomotic Complications in Bronchial Sleeve

Resections? World J Surg. 2019 Jan 18.















43. Bonanno L, Pavan A, Attili I, Pasello G, Guarneri V.

Immunotherapy in SCLC: Exceptional Clinical Benefit and

Abscopal Pneumonitis After Radiotherapy.

J Thorac Oncol. 2019 Jan;14(1):e5-e7.

FULL PAPER PUBLICATIONS IN PEER REVIEWED

JOURNALS WITHOUT IMPACT FACTOR

1) Favaretto AG, Pasello G, and Magro C

“Second and third line treatment in advanced non-small

cell lung cancer”. Discovery Medicine, 2009; 8 (43): 204-

209.

2) Pasello G, Altavilla G, Bonanno L, Rea F, Favaretto A.

“A pathological complete response after preoperative

chemotherapy with carboplatin and pemetrexed in

malignant pleural mesothelioma: a case report”. J Thorac

Disease 2010; 2: 254-257.

3) Polo V, Zago G, Frega S, Canova F, Bonanno L,

Favaretto A, Bonaldi L, Bertorelle R, Conte PF, Pasello G.

“Non-Small Cell Lung Cancer in a Very Young Woman: A

Case Report and Critical Review of the Literature”

American Journal of Case Reports, Nov 3;16:782-9

BOOK CHAPTER

- Giulia Pasello and Adolfo Favaretto. Neoadjuvant

Chemotherapy in Malignant Pleural Mesothelioma.

Malignant Mesothelioma Chapter 5 December 2012.

http://dx.doi.org/10.5772/47880

- Giovanni Luca Ceresoli, Giulia Pasello, Fiorella

Calabrese. ESMO book: Thoracic Tumours –Essentials

for Clinicians: Malignant Pleural Mesothelioma

March 2014

- OncologiaEdizione italiana a cura di Vittorina

Zagonel DE VITA - HELLMANN - LAWRENCE –



http://www.amjcaserep.com/authorsPanelManuscript/manuscript/idArt/894426/open/0

http://www.amjcaserep.com/authorsPanelManuscript/manuscript/idArt/894426/open/0

http://dx.doi.org/10.5772/47880



ROSENBERG (Piccin)

- Participation as a speaker and scientiific

committee to several national and international

conferences

- 2011- 2014 National AIOM (Associazione Italiana

di Oncologia Medica) young working group elected

member

- Reviewer of several peer reviewer journals

focused on thoracic oncology

- Member of ASCO since 2008; member of ESMO

and AIOM since 2009; member of IASLC since 2018

I authorize the handling of my personal data according to

Italian data protection Law.

PADOVA, 25/mar/2019

Europass Personal Information PASELLO GIULIAioveneto.it › wp-content › uploads › 2019 › 05...

Documents

Transcript of Europass Personal Information PASELLO GIULIAioveneto.it › wp-content › uploads › 2019 › 05...